Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus
Biotech
Cullinan's new data makes clearest case yet for autoimmune TCEs
When it comes to turning T-cell therapies to autoimmune diseases, CAR-Ts lead the way. But another red-hot modality is beginning to show potential.
James Waldron
Jun 6, 2026 5:15am
Cabaletta's autoimmune CAR-T strategy is built on 'durability'
Jun 4, 2026 8:26am
Odyssey CEO sees $304M IPO creating ‘little large pharma’
May 8, 2026 7:27am
Bain-backed Beeline buzzes out of stealth with $300M
Apr 15, 2026 7:00am
Biogen’s litifilimab sparkles in midphase lupus trial
Mar 30, 2026 4:45am
Amgen eyes lupus redemption while cancer candidate struggles
Feb 4, 2026 6:10am
